65,437 trials
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Transplant-related Mortality — 8 participants
Neuromuscular Blockade
Primary: Time From Start of Study Drug Administration to Recovery of the T4/T1 Ratio to 0.9 — 1.77; 14.80 minutes — p=<0.0001
Parkinson's Disease
Primary: Stride Length — 102.10; 112.30; 109.80; 111.20 cm
Paget's Disease of Bone
Primary: Number of Patients Who Achieve Therapeutic Response at 6 Months. — 85; 60 participants
Hepatitis C, Chronic
Primary: Change From Initiation of Pegasys Plus Copegus in log10 Hepatitis C Virus Ribonucleic Acid (HCV RNA) Viral Load to Week 12 of Anti-HCV Therapy — -3.5; -3.7 IU/mL
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L
Cannabis Use Disorders
Primary: Subjective Craving of Marijuana — 50.5; 52.3 Scores on a Scale
Healthy
Primary: Change From Baseline in Body Weight — 2.32; 4.23; 2.87 kilograms
Compulsive Buying
Primary: Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) — 22 units on a scale
Melanoma
Primary: Cumulative Participants Response to Palonosetron — 85; 139; 44; 72 episodes of nausea/vomiting
Kleptomania
Primary: Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS) — 3.83; 11.46 units on a scale
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 0.5; 3.6 percentage of ejection fraction — p=<0.05
Acute Migraine With or Without Aura in Adolescents
Primary: Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose — 322 participants
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Alzheimer Disease
Primary: Mean Cortical to Cerebellum SUVR — 1.665; 1.246 SUVR